Notification of Admission of Shares and TVR

AI SummaryClose X

Solvonis Therapeutics plc has announced the admission of 1,093,333,333 new ordinary shares to the London Stock Exchange's Main Market, bringing the total number of shares in issue to 7,899,736,826 as of September 30, 2026. These new shares are fully fungible with existing ordinary shares and were admitted on August 28, 2026. The total number of voting rights in the company is now 7,899,736,826, which shareholders can use for notification calculations under FCA rules.

Disclaimer*

UK 100

Latest directors dealings